
In first open-label phase 3 data from the ADEPT program, KarXT cut hallucination and delusion scores in Alzheimer disease psychosis, with no new safety signals.
Tell us about career, your experience, and your desire to help your patients. Help us help you do your job.
Tell us about career, your experience, and your desire to help your patients. Help us help you do your job.




